Department of Experimental Medicine - Section of Human Anatomy, University of Genova, Genova, Italy.
PLoS One. 2013 May 14;8(5):e63282. doi: 10.1371/journal.pone.0063282. Print 2013.
Leukocyte-associated Ig-like receptor (LAIR) is a small family-receptor able to inhibit immune cell function via collagen binding. It exists as both membrane-bound and soluble forms. LAIR-1 functions as an inhibitory receptor on natural killer cells, T lymphocytes and monocytes. In addition to LAIR-1, the human genome encodes LAIR-2, a soluble homolog. Several studies have focused on LAIR-1, whereas few investigations concentrate on the expression and function of LAIR-2. We demonstrate the presence of high LAIR-2 levels in 74/80 sera from patients with autoimmune thyroid diseases (both Graves' disease and autoimmune thyroiditis). LAIR-2 levels seemed not to be related to specific clinical manifestations, such as thyroid functions (hypo- or hyperthyroidism), or specific clinical features (such as ophtalmopathy). In addition, serum LAIR-2 is able, in vitro, to bind its natural ligand, collagen. Since LAIR-2 has been found to have higher affinity for collagens than LAIR-1 did, we hypothesize a potential regulating capability of serum LAIR-2 in finally regulating the inhibitory capability of LAIR-1.
白细胞相关免疫球蛋白样受体(LAIR)是一个小的家族受体,能够通过与胶原结合来抑制免疫细胞的功能。它存在于膜结合和可溶性两种形式。LAIR-1 作为自然杀伤细胞、T 淋巴细胞和单核细胞的抑制性受体发挥作用。除了 LAIR-1 之外,人类基因组还编码可溶性同源物 LAIR-2。已有多项研究集中在 LAIR-1 上,而对 LAIR-2 的表达和功能的研究较少。我们在 80 例自身免疫性甲状腺疾病(包括格雷夫斯病和自身免疫性甲状腺炎)患者的 74/80 份血清中证实了高水平的 LAIR-2。LAIR-2 水平似乎与特定的临床表现无关,如甲状腺功能(甲状腺功能减退或甲状腺功能亢进)或特定的临床特征(如眼病)。此外,血清 LAIR-2 能够在体外与其天然配体胶原结合。由于 LAIR-2 与胶原的亲和力高于 LAIR-1,我们假设血清 LAIR-2 可能具有潜在的调节能力,最终调节 LAIR-1 的抑制能力。